| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Original Studies |
Departments of Pediatric Endocrinology (B.I.H.-S., M.J.) and Physiological Chemistry (K.D.A.) and Center for Biomedical Genetics (K.D.A., P.C.v.d.V.), University Medical Center, 3508 AB Utrecht, The Netherlands; and Department of Pediatric Endocrinology, Emma Childrens Hospital Academic Medical Center (B.B.), 1105 AZ Amsterdam, The Netherlands
Address all correspondence and requests for reprints to: Maarten Jansen, M.D., Ph.D., Department of Pediatric Endocrinology, University Medical Center Utrecht, Room KC 03.063.0, P.O. Box 85090, 3508 AB Utrecht, The Netherlands. E-mail: m.jansen{at}wkz.azu.nl
The POU homeodomain containing transcriptional activator POU1F1,
formerly called Pit1 or GHF-1, is required for the embryological
determination and postnatal secretory function of the GH-, PRL-, and
TSH-producing cells in the anterior pituitary. Several mutations in the
gene encoding POU1F1 have been described, resulting in a syndrome of
combined pituitary hormone deficiency involving these three hormones.
Most of the patients with this phenotype have either a dominant
negative mutation in codon 271 (R271W) or are homozygous for a
recessive mutation in the POU1F1 gene; to date only one case has been
reported with compound heterozygosity for two point mutations. Here, we
describe a boy with severe deficiencies of GH, PRL, and TSH who had
compound heterozygosity for two novel point mutations in the POU1F1
gene: a 1-bp deletion frameshift mutation (747delA), the first one
described to date in this gene, which leads to a nonfunctional
truncated protein lacking the entire DNA recognition helix of the POU
homeodomain, and a missense mutation in the C-terminal end of the
fourth
-helix of the POU-specific domain (W193R),which causes a
500-fold reduction in the ability to bind to DNA and activate
transcription.
This article has been cited by other articles:
![]() |
I. Miyata, S. Vallette-Kasic, A. Saveanu, M. Takeuchi, H. Yoshikawa, A. Tajima, K. Tojo, R. Reynaud, M. Gueydan, A. Enjalbert, et al. Identification and Functional Analysis of the Novel S179R POU1F1 Mutation Associated with Combined Pituitary Hormone Deficiency J. Clin. Endocrinol. Metab., December 1, 2006; 91(12): 4981 - 4987. [Abstract] [Full Text] [PDF] |
||||
![]() |
R A Sporici, J S Hodskins, D M Locasto, L B Meszaros, A L Ferry, A M Weidner, C A Rinehart, J C Bailey, I M Mains, and S E Diamond Repression of the prolactin promoter: a functional consequence of the heterodimerization between Pit-1 and Pit-1 {beta} J. Mol. Endocrinol., October 1, 2005; 35(2): 317 - 331. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. A. van Tijn, J. J. M. de Vijlder, B. Verbeeten Jr., P. H. Verkerk, and T. Vulsma Neonatal Detection of Congenital Hypothyroidism of Central Origin J. Clin. Endocrinol. Metab., June 1, 2005; 90(6): 3350 - 3359. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Hashimoto, M. Cisternino, and L. E. Cohen A Novel Nonsense Mutation in the Pit-1 Gene: Evidence for a Gene Dosage Effect J. Clin. Endocrinol. Metab., March 1, 2003; 88(3): 1241 - 1247. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Kishimoto, Y. Okimura, K. Yagita, G. Iguchi, M. Fumoto, K. Iida, H. Kaji, H. Okamura, and K. Chihara Novel Function of the Transactivation Domain of a Pituitary-specific Transcription Factor, Pit-1 J. Biol. Chem., November 15, 2002; 277(47): 45141 - 45148. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. E. Cohen and S. Radovick Molecular Basis of Combined Pituitary Hormone Deficiencies Endocr. Rev., August 1, 2002; 23(4): 431 - 442. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |